Login to Your Account



Pfizer Phase III Failure Hints at ADC Shortcomings

By Marie Powers
Staff Writer

Tuesday, May 21, 2013
Late Monday, Pfizer Inc. disclosed its decision to halt a Phase III trial (B1931008) of inotuzumab ozogamicin, an investigational antibody-drug conjugate composed of a monoclonal antibody targeting CD22, administered in combination with Rituxan in relapsed or refractory CD22-positive aggressive non-Hodgkin's lymphoma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription